Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 18/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24739315 | 1.00 | KLKB1 (0.39) | KLKB1METTL3KDM4ENPC1LMNA | |
| SCHEMBL29305590 | 0.81 | KLKB1 (0.39) | KLKB1METTL3 | |
| SCHEMBL29957835 | 0.78 | METTL3 (0.38) | KLKB1METTL3 | |
| SCHEMBL20219591 | 0.78 | NPC1 (0.53) | KDM4ENPC1LMNAMAPTRAB9A | |
| SCHEMBL24738257 | 0.76 | METTL3 (0.39) | KLKB1METTL3 | |
| SCHEMBL29958329 | 0.76 | SMN1; SMN2 (0.42) | KLKB1METTL3KDM4ENPC1LMNA | |
| SCHEMBL27033743 | 0.75 | KLKB1 (0.40) | KLKB1METTL3 | |
| SCHEMBL24738256 | 0.75 | KLKB1 (0.38) | KLKB1METTL3KDM4ENPC1RAB9A | |
| SCHEMBL24729569 | 0.74 | METTL3 (0.39) | KLKB1METTL3KDM4ENPC1LMNA | |
| SCHEMBL29303098 | 0.74 | KLKB1 (0.40) | KLKB1METTL3KDM4ENPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |